HC Wainwright Reaffirms Buy Rating for Werewolf Therapeutics (NASDAQ:HOWL)

HC Wainwright reissued their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $15.00 target price on the stock.

A number of other research firms have also commented on HOWL. Wedbush reaffirmed an outperform rating and issued a $9.00 price objective on shares of Werewolf Therapeutics in a research note on Monday, June 3rd. JMP Securities restated a market outperform rating and set a $12.00 price objective on shares of Werewolf Therapeutics in a report on Wednesday, June 26th.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL opened at $2.14 on Tuesday. The firm has a market cap of $93.00 million, a price-to-earnings ratio of -1.96 and a beta of 0.46. Werewolf Therapeutics has a one year low of $1.57 and a one year high of $8.19. The company has a debt-to-equity ratio of 0.24, a current ratio of 6.71 and a quick ratio of 6.71. The stock’s fifty day moving average price is $4.18 and its two-hundred day moving average price is $5.07.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Friday, May 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.15%. The business had revenue of $0.74 million during the quarter, compared to the consensus estimate of $5.00 million. On average, equities analysts forecast that Werewolf Therapeutics will post -1.52 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors have recently bought and sold shares of HOWL. Financial Perspectives Inc boosted its position in Werewolf Therapeutics by 80.0% in the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after purchasing an additional 3,000 shares during the last quarter. Certuity LLC purchased a new stake in Werewolf Therapeutics during the 4th quarter worth about $39,000. Lighthouse Investment Partners LLC purchased a new stake in Werewolf Therapeutics during the 4th quarter worth about $87,000. Denali Advisors LLC purchased a new stake in Werewolf Therapeutics during the 1st quarter worth about $172,000. Finally, Acadian Asset Management LLC increased its stake in Werewolf Therapeutics by 119.8% in the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock worth $1,119,000 after acquiring an additional 94,212 shares during the last quarter. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.